| Wang, Qing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 04/25 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
CTP-MCVF-003, NCT06226714: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds |
|
|
| Active, not recruiting | 3 | 840 | RoW | MCV4, MPSV4 | CanSino Biologics Inc. | Meningococcal Meningitis | 10/24 | 10/24 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
| Liu, Xiaoqiang |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT04644484: A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety |
|
|
| Completed | 3 | 1000 | RoW | SYN023, A Humanized Anti-Rabies Molecular antibodies cocktails, Human Rabies Immune Globulin (HRIG), Rabies Vaccine, Freeze-dried Rabies Vaccine for Human Use (Vero Cells) | Synermore Biologics (Suzhou) Co., Ltd., Simoon Record Pharma Information Consulting Co., Ltd. | Rabies, Communicable Disease, Virus Diseases, Rhabdoviridae Infections, Mononegavirales Infections, RNA Virus Infections | 06/22 | 12/22 | | |
| Completed | 3 | 1200 | RoW | GR1801, Human Rabies Immunoglobulin(HRIG), Rabies Vaccine | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Rabies Post-exposure Prophylaxis | 09/23 | 09/24 | | |
NCT06331156 / 2022-000708-36: A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants |
|
|
| Completed | 3 | 400 | RoW | HRV PCV-free, Rotarix PCV-free, IPV, Beijing Biological Products Institute Co.,Ltd.'s Inactivated Poliomyelitis Vaccine Made From Sabin Strains (Vero Cells) | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Gastroenteritis | 10/24 | 10/24 | | |
NCT06025695 / 2020-000972-38: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks |
|
|
| Completed | 3 | 2000 | RoW | GSK's liquid oral live attenuated HRV, Rotarix, PCV-free liquid formulation of GSK's oral live attenuated HRV, Rotarix PCV-free | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Gastroenteritis | 05/24 | 10/24 | | |
NCT06482216: Correlation of Protection Against Varicella in an Exploratory Study |
|
|
| Not yet recruiting | N/A | 400 | NA | Varicella vaccine | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Varicella | 05/27 | 10/28 | | |
| Fang, Xing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT06678373: Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas |
|
|
| Active, not recruiting | 4 | 250 | RoW | Liaoning Chengda Inactivated Japanese Encephalitis Vaccine | Liaoning Chengda Biotechnology CO., LTD | Japanese Encephalitis | 04/26 | 12/26 | | |
| Sun, Zhaodan |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Wang, Fubing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Zhang, Dongjuan |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT06564116: Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above |
|
|
| Completed | 4 | 612 | RoW | Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli), Recombinant Hepatitis E Vaccine (Escherichia Coli) | Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Fujian | Hepatitis E | 03/24 | 03/24 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Guo, Shicheng |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Tong, Yeqing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Deng, Qiuyun |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Zhang, Ruizhi |
NCT05453487: Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine |
|
|
| Recruiting | 4 | 360 | RoW | coadministration, COVID-19 vaccine, rabies vaccine | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd., Changchun Institute of Biological Products Co., Ltd. | COVID-19, Rabies | 10/22 | 06/23 | | |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT05480436: Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population |
|
|
| Recruiting | 4 | 1200 | RoW | coadministration, COVID-19 vaccine, IIV4+PPV23 | China National Biotec Group Company Limited, Hunan Provincial Center for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Xiangya Hospital of Central South University, Beijing Institute of Biological Products Co Ltd., Chengdu Institute of Biological Products Co.,Ltd., Shanghai Institute Of Biological Products | Hemolysis, COVID-19 | 01/23 | 07/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
| Zhang, Xiaoshu |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
